// App-Quantinova.ai

AB0890 (2022) : Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Researchers

Presenter

  • R. B. Warren

Principal Investigators

  • A. Armstrong

  • M. Gooderham

  • B. Strober

  • D. Thai

  • S. Imafuku

  • H. Sofen

  • L. Spelman

  • N. J. Korman

  • M. Zheng

  • E. Colston

  • J. Throup

  • S. Kundu

  • R. Kisa

  • S. Banerjee

  • A. Blauvelt

Medical Centers

  • The Dermatology Centre, Salford Royal NHS Foundations Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, University of Manchester, Manchester, UK

  • Keck School of Medicine, University of Southern California, Clinical Research, Los Angeles, United States of America

  • SKiN Center for Dermatology, Queen’s University and Probity Medical Research, Peterborough, Canada

  • Yale University, New Haven, and Central Connecticut Dermatology Research, Dermatology, Cromwell, United States of America

  • University of Lubeck, Dermatology, Lubeck, Germany

  • Fukuoka University Hospital, Fukuoka, Japan

  • UCLA School of Medicine, Dermatology, Los Angeles, United States of America

  • Veracity Clinical Research, Dermatology, Queensland, Australia

  • Case Western Reserve University and University Hospitals, Dermatology, Cleveland, United States of America

  • Second Affiliated Hospital, Zhejiang University, School of Medicine, Dermatology, Zhejiang, China

  • Bristol-Myers Squibb, former employee, Princeton, United States of America

  • Bristol Myers Squibb, Rheumatology and Dermatology, Princeton, United States of America

  • Oregon Medical Research Center, Dermatology, Portland, United States of America

Locations

  • United Kingdom

  • United States

  • Canada

  • Germany

  • Japan

  • Australia

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT03881059

  • NCT03624127

  • NCT03611751

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved